Report Highlights

U.S. Healthcare Cold Chain: Market Overview

The U.S. healthcare cold chain logistics market reached USD 27.4 billion in 2024 and operates under a layered regulatory architecture in which federal agencies define product standards while private operators build the physical network. Cencora, Cardinal Health and McKesson control pharmaceutical distribution, running temperature-controlled facilities validated to USP General Chapter <1079> storage and transportation requirements. Specialist carriers such as UPS Healthcare and FedEx Custom Critical handle biologics and vaccines that require 2–8°C or frozen handling, creating a tiered service structure.

Government has been the dominant force in standard-setting and purchasing rather than in physical operations. The CDC's Vaccines for Children program, authorized under Section 1928 of the Social Security Act, and the Strategic National Stockpile managed by the Administration for Strategic Preparedness and Response create demand that private operators serve under federal contract. Private capital has led network build-out, with Lineage and Americold investing in pharmaceutical-grade cold storage independent of federal funding, producing a compliance-heavy, contract-driven market.

Policy-Driven Growth in U.S. Healthcare Cold Chain

The Drug Supply Chain Security Act, enacted in November 2013 as Title II of the Drug Quality and Security Act (Public Law 113-54), requires product-level electronic traceability under Section 582 of the Federal Food, Drug, and Cosmetic Act. FDA enforces interoperable exchange of transaction information, with phase-in dates culminating in November 2024. Each compliant shipment now requires verified data alongside temperature records, which raised demand for validated warehouse systems and data-capable cold storage at distributors and third-party logistics providers across the country.

The American Innovation and Manufacturing Act of 2020 directs EPA to phase down hydrofluorocarbons, cutting consumption allowances to 60 percent of baseline in 2024 and 30 percent in 2029 under its Technology Transitions rule. Operators must replace high-global-warming-potential refrigeration in cold rooms and reefer units, which translates directly into retrofit and equipment replacement demand. Separately, the CDC's Vaccines for Children program, which supplies vaccines to roughly half of US children, requires storage and transport that complies with the CDC Vaccine Storage and Handling Toolkit, generating recurring demand for validated refrigerated transport.

Regulatory Barriers and Compliance Costs

Third-party logistics providers must hold licensure under Section 584 of the Federal Food, Drug, and Cosmetic Act, with FDA setting minimum licensing standards and state boards of pharmacy issuing licenses. Application timelines vary by state, and multi-state operators must maintain separate licenses and inspection readiness in every state where they hold product. Wholesale distributor licensing, administered by the same state boards, adds parallel filings that delay the opening of new distribution centers.

Environmental and transport rules add recurring costs. EPA administers refrigerant management under Section 608 of the Clean Air Act alongside the AIM Act's Technology Transitions rule, which restricts high-global-warming-potential refrigerants in new commercial refrigeration with phased compliance dates beginning in 2025. Dry ice used for ultra-cold shipments is a Class 9 hazardous material regulated by PHMSA under 49 CFR Parts 171 to 180, and hazmat employees must complete recurrent training at least every three years under 49 CFR 172.704.

Policy-Created Opportunities in the U.S.

The CDC's Vaccines for Children program and the Strategic National Stockpile create federally funded demand for validated cold chain services. Contract awards for vaccine and countermeasure distribution favor operators holding FDA-compliant data systems and validated 2–8°C and frozen capacity, giving UPS Healthcare and Cencora a structural advantage in public-sector bids. Regional 3PLs that qualify for federal subcontracting roles gain access to volume without building national networks.

DSCSA interoperability has created a market for traceability-as-a-service, in which operators sell compliant transaction-data exchange to smaller manufacturers and dispensers. The small-dispenser exemption, extended to November 2025, shifts compliance responsibility onto outsourced 3PLs and opens recurring data-service revenue. Separately, EPA's Significant New Alternatives Policy program lists natural refrigerants, including CO2 and propane, as acceptable alternatives, creating a retrofit opportunity for operators replacing HFC systems in pharmaceutical cold rooms.

Market at a Glance

Leading Market Participants

• UPS Healthcare
• FedEx Custom Critical
• DHL Supply Chain
• Cencora
• Cardinal Health
• McKesson
• Americold Realty Trust
• Lineage, Inc.
• Cryoport, Inc.
• Kuehne+Nagel

Regulatory and Policy Environment

The primary legislation is the Drug Supply Chain Security Act, enacted as Title II of the Drug Quality and Security Act (Public Law 113-54) and codified in Section 582 of the Federal Food, Drug, and Cosmetic Act, administered by FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Key compliance requirements include transaction information, transaction history, and transaction statements, plus verification of product identifiers at the saleable unit level. Environmental compliance falls under the AIM Act, administered by EPA's Office of Air and Radiation, while vaccine storage is governed by CDC guidance tied to the Vaccines for Children program.

Upcoming changes include full DSCSA interoperability enforcement and the AIM Act's 2029 allowance step-down to 30 percent of baseline. Compared with regional peers, the U.S. framework is more fragmented: the European Union harmonized serialization through the Falsified Medicines Directive (2011/62/EU), operating the European Medicines Verification System since February 2019, while Canada licenses drug wholesalers federally under Part C of its Food and Drug Regulations. U.S. operators therefore layer federal rules over 50 state licensing regimes, raising multi-state compliance costs relative to EU and Canadian peers.

Long-Term Policy Outlook for U.S. Cold Chain

By 2032, the Inflation Reduction Act's Medicare drug price negotiation will reshape demand. The third negotiation cycle, effective in 2028, extends to Part B drugs, which are typically administered in clinics and infusion centers and require refrigerated distribution to the point of care. This shifts volume from retail pharmacy channels toward specialty distributors able to maintain 2–8°C integrity through to the clinic door.

Continued HFC phasedown under the AIM Act will drive equipment replacement through 2029, after which the 30 percent allowance level forces wide adoption of natural refrigerants. DSCSA enforcement will consolidate operators with verified data exchange capability, while FDA's licensing scrutiny of third-party logistics providers will shrink the pool of qualified regional operators. Market growth to USD 55.8 billion by 2032 will therefore favor scale operators with multi-state licensing and validated multi-temperature networks.